Loading viewer...
investor_presentation
Format: PDF investor_presentation
2020 INTERIM RESULTS PRESENTATION For the six months ended 31 December 2019
2020 INTERIM RESULTS PRESENTATION
For the six months ended 31 December 2019DISCLAIMER
We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future r esults and
estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S. Private Securities Lit igation Reform Act
of 1995. Words such as “prospects”, “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may ”, “ endeavour ” and
“project” and similar expressions are intended to identify such forward looking statements, but are not the exclusive means o f identifying such
statements. By their very nature, forward -looking statements involve inherent risks and uncertainties, both general and specific , and there are
risks that predictions, forecasts, projections and other forward -looking statements will not be achieved. If one or more of thes e risks materialise ,
or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors th at could cause our
actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forw ard-looking
statements are discussed in each year’s annual report.
Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of t he Listings
Requirements of the JSE Limited, any obligation to update or revise any of them, whether as a result of new information, futu re events or
otherwise. Any profit forecasts published in this report are unaudited and have not been reviewed or reported on by Aspen's e xternal auditors.
2CAUTIONARY REGARDING FORWARD -LOOKING STATEMENTSDISCLOSURE NOTE
•Results separately disclose discontinued operations arising from the completed disposals of the Nutritionals business, Non -core
pharmaceutical portfolio in the Asia Pacific region, Japanese business and Public sector ARVs.
•Adoption of new IFRS 16 Leases
Retrospectively applied from 1 July 2019, using a modified retrospective approach
Comparatives are not restated under this approach
Turkey has been moved to MENA from Developed Europe and consequently comparatives have been restated to reflect this segmental
3FINANCIAL REVIEWFINANCIAL SUMMARY
*CER reflects the underlying operational performance. H1 2019 restated at H1 2020 average exchange rates
^ Calculated in terms of Facilities Agreement covenant measureR’million% Change vs PY
H1 2020 Reported CER *
Net revenue 18 417 3% 3%
Gross profit 9 410 -3% -3%
Gross profit margin 51.1% 54.1% 54.0%
Normalised EBITDA 5 260 0% 0%
Normalised EBITDA margin 28.6% 29.3% 29.3%
Preview truncated — download the full document for the complete content.
investor_presentation
59 Pages
UGE International